Comparative Pharmacology
Head-to-head clinical analysis: DRIZALMA SPRINKLE versus SAVELLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRIZALMA SPRINKLE versus SAVELLA.
DRIZALMA SPRINKLE vs SAVELLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibition, resulting in increased synaptic serotonin concentrations and enhanced serotonergic neurotransmission.
Selective serotonin and norepinephrine reuptake inhibitor (SNRI); also weakly inhibits dopamine reuptake. Binds to serotonin and norepinephrine transporters, increasing their extracellular concentrations.
60 mg orally once daily, with or without food. Capsules may be swallowed whole or opened and sprinkled onto applesauce.
100 mg orally twice daily; may initiate at 50 mg twice daily and increase to 100 mg twice daily after 1 week.
None Documented
None Documented
12-15 hours; steady-state achieved in 2-3 days; no significant accumulation with q12h dosing.
Approximately 11 hours for milnacipran (SAVELLA). In the context of twice-daily dosing, steady state is reached within 2-3 days.
Primarily renal (approx. 70% as unchanged drug and metabolites); 30% fecal/biliary.
Renal excretion of unchanged drug and metabolites accounts for approximately 51-58% of the dose. Fecal excretion accounts for about 19-22%. The remainder is eliminated via other routes (e.g., oxidative metabolism and subsequent conjugation).
Category C
Category C
SNRI Antidepressant
SNRI Antidepressant